meta
|
evidence
COVID-19
Living systematic review and meta-analysis
regdanvimab (Regkirona- CT-P59-Celltrion)
All
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, pre-admission
anticoagulant, prophylactic dose
anticoagulation, intermediate prophylactic dose
Bivalirudin
enoxaparin
heparin at therapeutic dose
P2Y12 inhibitors
rivaroxaban
sulodexide
face mask
febuxostat
hydrogen-oxygen nebulizer
hyperbaric oxygen
nintedanib
paracetamol
pulmonary rehabilitation
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab
otilimab
clarithromycine
colchicine
Colchicine plus rosuvastatin
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
selinexor
sodium aescinate
stem cells
tradipitant
vilobelimab (IFX-1)
Apilimod
corticosteroids
ciclesonide
dexamethasone
Dexamethasone 12mg
dexamethasone 6mg
Hydrocortisone
low-dose corticosteroids
methylprednisolone
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
Deferred Convalescent plasma
Early convalescent plasma.
immunoglobulin therapy
inactivated mycobacterium vaccine
interferon
IFN beta-1a
high-dose IFN beta-1a
IFN beta-1b
IFN gamma
inhaled interferon
IFN alpha
pegylated interferon-α2b
recombinant super-compound interferon rSIFN-co
SNG001 inhaled interferon beta
interferon / TFF2
peginterferon
PNB001
Interleukin-2
levamisole
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
bamlanivimab monotherapy
bamlanivimab/etesevimab
Bebtelovimab (LY-CoV1404)
bevacizumab
cilgavimab and tixagevimab (Evusheld)
equine polyclonal antibodies INM005
regdanvimab (Regkirona- CT-P59-Celltrion)
sotrovimab (Xevudy; VIR-7831)
XAV-19
rhG-CSF
Immunosuppressants drugs
adalimumab
anakinra
anti-interleukin-6
clazakizumab
Levilimab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
canakinumab
complement inhibitors
conestat alfa
ravulizumab
CRAC-channel inhibitors (auxora)
eculizumab
emapalumab
fostamatinib
itolizumab
ixekizumab
jakotinib
janus kinase (JAK) inhibitor
baricitinib
baricitinib plus remdesivir
ruxolitinib
TD-0903
TD-0903 10mg
TD-0903 1mg
TD-0903 3mg
tofacitinib
lenzilumab
pamrevlumab
tacrolimus
tetrandrine
thalidomide
inhaled corticosteroids
budesonide
Kinase inhibitors
acalabrutinib
imatinib
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
Atorvastatin
thymosin
antiandrogenic
5-alpha-reductase inhibitors
dutasteride
progesterone
proxalutamide
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
bromhexine
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
zinc plus hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
Emtricitabine/tenofovir plus colchicine plus rosuvastatin
favipiravir
favipiravir plus interferon
fluvoxamine
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
Interferon plus lopinavir/ritonavir
ivermectin
ivermectin plus doxycycline
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
Lopinavir/ritonavir plus hydroxychloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
molnupiravir
niclosamide
nirmatrelvir / ritonavir (Paxlovid)
nitazoxanide
opaganib
oseltamivir
oseltamivir plus chloroquin
remdesivir
ribavirin
ritonavir
sofosbuvir
sofosbuvir and daclatasvir
sofosbuvir and ledipasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
tranilast
triazavirin
umifenovir (arbidol)
zinc
control
placebo
prone positioning
standard of care
miscellaneous
acetylcysteine
alpha lipoic acid
anti-CK2
Aspirin
aviptadil
calcium channel blocker
camostat mesilate
Cannabidiol
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
dornase alfa
expectorants and mucolytics
kinin-kallikrein inhibitors
melatonin
mouthrise and gargling agents
mouthrinses
N-Acetylcysteine
nasal spray
nasal spray containing Iota-Carrageenan
natural killer (NK) cells
nicotin
nigella sativa oil
nitric oxide (gas Inhalation or releasing solution)
omega-3 Polyunsaturated Fatty Acids
ozonated autohemotherapy
plasma exchange
povidone-iodine
previfenon (EGCG)
prostacyclin
PUL-042 inhalation solution
pyridostigmine
radiotherapy
sabizabulin
sildenafil
triiodothyronine (T3)
Oral antidiabetic drugs
dapagliflozin
DPP-4 inhibitor
metformin
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
losartan
angiotensin-(1-7)
continuation of ACEI/ARB
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
vaccines
BCG vaccination
CoVLP (MT-2766, Medicago)
DNA vaccine
Zy-Cov-D (Zydus Cadila)
ebola vaccine
first booster dose
heterologous prime-boost
Inactivated virus vaccine
CoronaVac (SinoVac)
Covaxin, Bharat Biotech (BBV152)
Shifa-Pharmed inactivated vaccine
Sinopharm Beijing (BBIBP-CorV)
Sinopharm Wuhan
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
CureVac
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus)
Ad26.ZEBOV ()
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine)
CanSino (Convidecia)
Covishield (Oxford/AZ formulation)
Janssen AD26 vaccine (JNJ-78436735)
Sputnik V (Gam-COVID-Vac)
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
protein subunit vaccine
Anhui Zhifei Longcom
CoVax-19 SpikoGen
Nuvaxovid (NVX-CoV2373) Novavax
Sanofi/GSK recombinant protein vaccine
SCB-2019
Replicating Viral Vector
seasonal influenza vaccines
virus-like particles vaccine
Medicago
Vitamins
vitamin C
zinc plus vitamin c
Vitamin D
secondary prevention
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention
vs. potential COVID-19 treatments
vs. control
vs. placebo
patient subgroup...
age >= 65 yr
subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Studies
Mapping
Meta-analysis
Excluded
1
table
network
network 2
select an endpoint to display result....
display studies
----
color = results
color = ROB
demonstrated
suggested
inconclusive
safety concern
ongoing study
not assessable
low
moderate
serious
ongoing study
display ongoing
demontrated benefit only
Nothing for this selection!